Navigation Links
Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
Date:11/13/2007

Product Shipments Begin November 15th, 2007

BASKING RIDGE, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Inc., wholly-owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), today announced that it had entered into a five-year $20,000,000 contract to be the exclusive provider of nutritional products to Provider Services Inc. (PSI) of Cleveland, Ohio. The contract will commence immediately with PSI purchasing Millennium's Resurgex Select(TM) line of products.

PSI is Ohio's second largest services provider for the Long Term Care community with over 5,000 beds. It will care for over 12,000 residents in the upcoming year with revenues exceeding $300 Million.

Brian Colleran, CEO of PSI, stated, "Millennium Biotechnologies has developed an economically viable nutritional product that, in our judgment, is superior to other nutritional products on the market today. Resurgex Select(TM) will help our clients maintain proper nutrition and avoid development of clinical problems. Our focus is to provide our clients with the best products on the market and we believe Millennium's lines fit this criteria. My favorable review of the Millennium product line recently motivated me to make a substantial personal investment in the Company's common stock."

Kevin Daubenmire MSA/RDLD/LNHA, Corporate Dietician for PSI, added: "The Millennium products are clearly nutritionally superior with strong client acceptance, and they are cost efficient. I have been particularly impressed with the diverse flavor profiling which is a distinct advantage over all other products on the market. I believe that these products, in both powdered and RTD formats, will become a new nutritional standard in the rapidly growing Long Term Care industry. As a former corporate clinical services Dietician for the largest LTC Provider in the US, I managed dieticians at a divisional level. My experience has shown that the choice of supplement intervention translates directly to improving a patient's quality of life."

Mark Mirken, President and Chief Operating Officer of Millennium, stated: "Our prior experience in the onocological and immunocompromised arenas enables us to deliver a substantially similar benefits profile in the Long Term Care channel. Resurgex Select(TM), in both a powdered and liquid format, creates a new and compelling revenue proposition for our Company. It allows us to leverage the extensive research and development dollars previously expended by us into new products in one of the fastest growing market segments."

"Millennium's product is both calorically dense while simultaneously delivering an array of neutraceutical ingredients to support the long term care population. This product's launch is a paradigm shift in the way nutrition is perceived and prescribed in the overall treatment of the elderly, the fastest growing segment of our population."

He added: "Our competition in this multi-billion dollar business does not sufficiently address the full nutritional needs of the Elderly patient. We are truly excited about our first incursion into this channel and hope to develop a much larger footprint worldwide."

About Millennium:

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also recently developed a Surgex(R) sports nutrition formula, clinically proven to address the nutritional concerns of both professional and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immunocompromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC").


'/>"/>
SOURCE Millennium Biotechnologies Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
2. Synova Healthcare to Participate in Womens Health Care in the New Millennium Conference, as Retail Distribution for the Fem-V(R) Test Kit Expands
3. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
4. 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation
5. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
6. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
7. Pot bellies linked to early signs of cardiovascular disease
8. MSU engineering team designs innovative medical device
9. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
10. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
11. Gov. Blagojevich Signs Bill Improving Illinois Mental Illness Treatment Law
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... With ProGlass Prism users now have the ability to ... control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position ... With ProGlass Prism users are given the tools and effects to generate a ...
(Date:2/24/2017)... ... 24, 2017 , ... The Radiology Business Management Association will select ... the annual Building Better Radiology Marketing Programs conference, held this year from ... Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon ... TV’s “Mama June: From Not to Hot,” which will begin airing on February 24, ... known to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” ...
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at 10075 ... Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... who have earned high ratings and superior patient reviews from multiple credible sources. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24. Februar 2017 ITL Limited, ( ... Gesundheitsbereiches, ist erfreut, für das zum 31. Dezember ... Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine vollständige ... Wachstum" finden Sie hier . ... Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... Feb. 23, 2017  This report analyzes the worldwide ... following Products: Intermediates, Analytical, and Others. ... include Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive ... Europe , and Rest of World. ... 2015 through 2022. Also, a six-year historic analysis is ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) today announced ... Directors that will be submitted to the 2017 Annual ... the company,s three largest shareholders at the end of ... seat on the Nomination Committee, and the Chairman of ... was as follows:  Anders ...
Breaking Medicine Technology: